Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Paging Dr. McClellan: FDA Calls On Brookings For PDUFA Research

This article was originally published in The Pink Sheet Daily

Executive Summary

Brookings’ Engelberg Center for Health Care Reform invited to help FDA research REMS and risk-benefit standardization, patient-reported outcomes, and other issues that were mandated in PDUFA V.

You may also be interested in...



Biomarker Development Meeting May Help Expand Accelerated Approval

FDA could develop more guidance on how sponsors can qualify potential surrogate endpoints.

Biomarker Development Meeting May Help Expand Accelerated Approval

FDA could develop more guidance on how sponsors can qualify potential surrogate endpoints.

“Complete Response” Letters Might Include Benefit-Risk Framework Discussion

FDA official says idea could be helpful; meanwhile, sponsors and others remain concerned about the framework’s undefined decision-making methods.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS075386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel